Christos Fokoloros
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Christos Fokoloros has a total of 86 co-authors. Here are the top co-authors by number of shared publications:
Alexandros Katoulis
2nd Department of Dermatology & Venereology, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece
2 shared publications- Maria Kinali
Chelsea and Westminster NHS Foundation Trust
2 shared publications - Michael Makris
Allergy Unit, 2nd Department of Dermatology and Venereology, National and Kapodistrian University of Athens, University General Hospital ‘Attikon’, 12462 Athens, Greece
2 shared publications Sotirios Papageorgiou
Hematology Unit, 2nd Department of Internal Medicine, Propaedeutic, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece
2 shared publicationsVasilliki Pappa
Hematology Unit, 2nd Department of Internal Medicine, Propaedeutic, Medical School, National and Kapodistrian University of Athens, Attikon University Hospital, Athens, Greece
2 shared publicationsAhmed Karim
Royal Marsden NHS Foundation Trust, London, United Kingdom
1 shared publication
Latest Publications
- Open Access
- 27 April 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (9) , 1713-1724
Mast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry
Mast cell leukemia (MCL) is a rare subtype of systemic mastocytosis defined by ≥20% mast cells (MC) on a bone marrow aspirate. We evaluated 92 patients with MCL from the European Competence Network on Mastocytosis registry. Thirty-one (34%) patients had a diagnosis of MCL with an associated hematologic neoplasm (MCL-AHN). Chronic MCL (lack of C-findings) comprised 14% of patients, and only 4.5% had “leukemic MCL” (≥10% circulating MCs). KIT D816V was found in 62/85 (73%) evaluable patients; 9 (11%) individuals exhibited alternative KIT mutations, and no KIT variants were detected in 14 (17%) subjects. Ten evaluable patients (17%) had an abnormal karyotype and the poor-risk SRSF2, ASXL1, and RUNX1 (S/A/R) mutations were identified in 16/36 (44%) patients who underwent next-generation sequencing. Midostaurin was the most common therapy administered to 65% of patients and 45% as first-line therapy. The median overall survival (OS) was 1.6 years. In multivariate analysis (S/A/R mutations excluded owing to low event rates), a diagnosis of MCL-AHN (hazard ratio [HR], 4.7; 95% confidence interval [CI], 1.7-13.0; P = .001) and abnormal karyotype (HR, 5.6; 95% CI, 1.4-13.3; P = .02) were associated with inferior OS; KIT D816V positivity (HR, 0.33; 95% CI, 0.11-0.98; P = .04) and midostaurin treatment (HR, 0.32; 95% CI, 0.08-0.72; P = .008) were associated with superior OS. These data provide the most comprehensive snapshot of the clinicopathologic, molecular, and treatment landscape of MCL to date, and should help further inform subtyping and prognostication of MCL.
- 27 April 2023
- Published by American Society of Hematology in Blood Advances
- Vol. 7 (9) , 1713-1724
Open AccessMast cell leukemia: clinical and molecular features and survival outcomes of patients in the ECNM Registry
Mast cell leukemia (MCL) is a rare subtype of systemic mastocytosis defined by ≥20% mast cells (MC) on a bone marrow aspirate. We evaluated 92 patients with MCL from the European Competence Network on Mastocytosis registry. Thirty-one (34%) patients had a diagnosis of MCL with an associated hematologic neoplasm (MCL-AHN). Chronic MCL (lack of C-findings) comprised 14% of patients, and only 4.5% had “leukemic MCL” (≥10% circulating MCs). KIT D816V was found in 62/85 (73%) evaluable patients; 9 (11%) individuals exhibited alternative KIT mutations, and no KIT variants were detected in 14 (17%) subjects. Ten evaluable patients (17%) had an abnormal karyotype and the poor-risk SRSF2, ASXL1, and RUNX1 (S/A/R) mutations were identified in 16/36 (44%) patients who underwent next-generation sequencing. Midostaurin was the most common therapy administered to 65% of patients and 45% as first-line therapy. The median overall survival (OS) was 1.6 years. In multivariate analysis (S/A/R mutations excluded owing to low event rates), a diagnosis of MCL-AHN (hazard ratio [HR], 4.7; 95% confidence interval [CI], 1.7-13.0; P = .001) and abnormal karyotype (HR, 5.6; 95% CI, 1.4-13.3; P = .02) were associated with inferior OS; KIT D816V positivity (HR, 0.33; 95% CI, 0.11-0.98; P = .04) and midostaurin treatment (HR, 0.32; 95% CI, 0.08-0.72; P = .008) were associated with superior OS. These data provide the most comprehensive snapshot of the clinicopathologic, molecular, and treatment landscape of MCL to date, and should help further inform subtyping and prognostication of MCL.
- Open Access
- 9 January 2023
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 103, adv00845
Mastocytosis in the Skin: Disease Heterogeneity among Children and Adults
Is missing (Short communication)
- 9 January 2023
- Published by Medical Journals Sweden AB in Acta Dermato-Venereologica
- Vol. 103, adv00845
Open AccessMastocytosis in the Skin: Disease Heterogeneity among Children and Adults
Is missing (Short communication)
- Open Access
- 3 November 2022
- Published by Hindawi Limited in Case Reports in Hematology
- Vol. 2022, 1-3
Systemic Mastocytosis in a Patient with BCR-ABL1-Positive Chronic Myeloid Leukemia in the Remission Phase
Systemic mastocytosis (SM) comprises a group of rare disorders resulting from tissue infiltration by pathological mast cells. In a percentage ranging from 5 to 40 in various patient series, SM appears to be associated with an accompanying hematologic neoplasm (SM-AHN). The coexistence of SM with chronic myelogenous leukemia (CML) is extremely rare with only 3 cases in the literature. The natural course of CML has changed dramatically over the past 2 decades with the use of tyrosine kinase inhibitors (TKIs). We report a case of diagnosing SM in a patient in complete molecular remission of CML after stopping TKI treatment.
- 3 November 2022
- Published by Hindawi Limited in Case Reports in Hematology
- Vol. 2022, 1-3
Open AccessSystemic Mastocytosis in a Patient with BCR-ABL1-Positive Chronic Myeloid Leukemia in the Remission Phase
Systemic mastocytosis (SM) comprises a group of rare disorders resulting from tissue infiltration by pathological mast cells. In a percentage ranging from 5 to 40 in various patient series, SM appears to be associated with an accompanying hematologic neoplasm (SM-AHN). The coexistence of SM with chronic myelogenous leukemia (CML) is extremely rare with only 3 cases in the literature. The natural course of CML has changed dramatically over the past 2 decades with the use of tyrosine kinase inhibitors (TKIs). We report a case of diagnosing SM in a patient in complete molecular remission of CML after stopping TKI treatment.
- Open Access
- 25 April 2021
- Published by Knowledge E DMCC in Iranian Journal of Allergy, Asthma and Immunology
- Vol. 20 (2) , 255-258
Generalized Bullous Fixed Drug Eruption to Fluconazole with Positive Patch Testing and Confirmed Tolerance to Itraconazole
Generalized bullous fixed drug eruption (GBFDE) is a specific variant of fixed drug eruption that belongs to severe cutaneous adverse reactions (SCARs) and its diagnosis is based mainly on clinical course and especially on the reoccurrence of typical bullous lesions in previous and new sites after re-administration of the offending drug. We present a well-documented case of fluconazole-induced GBFDE, with a positive patch test to fluconazole (30% weight/volume preparation) and clinical tolerance to itraconazole proven by negative oral provocation. Even in SCARs, patch testing represents a useful diagnostic tool, while oral provocation remains the gold standard in cases that an alternative but the chemically relevant drug must be administered.
- 25 April 2021
- Published by Knowledge E DMCC in Iranian Journal of Allergy, Asthma and Immunology
- Vol. 20 (2) , 255-258
Open AccessGeneralized Bullous Fixed Drug Eruption to Fluconazole with Positive Patch Testing and Confirmed Tolerance to Itraconazole
Generalized bullous fixed drug eruption (GBFDE) is a specific variant of fixed drug eruption that belongs to severe cutaneous adverse reactions (SCARs) and its diagnosis is based mainly on clinical course and especially on the reoccurrence of typical bullous lesions in previous and new sites after re-administration of the offending drug. We present a well-documented case of fluconazole-induced GBFDE, with a positive patch test to fluconazole (30% weight/volume preparation) and clinical tolerance to itraconazole proven by negative oral provocation. Even in SCARs, patch testing represents a useful diagnostic tool, while oral provocation remains the gold standard in cases that an alternative but the chemically relevant drug must be administered.
- 1 November 2018
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 14 (11) , 1652-1658
The effect of laparoscopic sleeve gastrectomy on quality of life: A prospective cohort study with 5-years follow-up
- 1 November 2018
- Published by Elsevier in Surgery for Obesity and Related Diseases
- Vol. 14 (11) , 1652-1658
The effect of laparoscopic sleeve gastrectomy on quality of life: A prospective cohort study with 5-years follow-up
- 1 March 2015
- Published by Georg Thieme Verlag KG in Journal of Pediatric Neurology
- Vol. 13 (01) , 016-021
Clinical Assessment and Differential Diagnosis of Pediatric Pseudotumor Cerebri Syndrome: Pearls and Pitfalls
Pseudotumor cerebri syndrome (PTCS) is defined by the presence of elevated intracranial pressure in the setting of normal brain parenchyma and normal cytologic and chemical analyses of the cerebrospinal fluid. Pathophysiology of this syndrome remains unclear, while its incidence may be potentially rising in children. The presenting signs and symptoms of PTCS are heterogeneous to usually include headache, papilledema, and visual disturbances (i.e., vision loss or double vision). The clinical features of PTCS in children have changed over the years, making the diagnosis challenging in some cases. Young children may present with atypical symptoms, such as those mimicking a posterior fossa tumor. There are reports of PTCS in children in the absence of headache. Papilledema, considered the acute hallmark of PTCS at onset, can also be absent. It is thus important for pediatricians to recognize atypical presentations especially as previous studies have suggested children presenting with headache in the absence of papilledema or those with papilledema in the absence of any other clinical signs may have increased risk of developing visual constriction deficits and permanent loss of vision, respectively. Moreover, many conditions in the pediatric age group may mimic PTCS, such as migraine and tension headaches. Cerebral venous sinus thrombosis and some neoplastic processes such as gliomatosis cerebri and leptomeningeal spread of hematologic malignancies are known to augment intracranial pressure and have to be carefully excluded. To avoid misdiagnosis and potential long-term sequel, a thorough clinical assessment is crucial to promptly and correctly recognize PTCS.
- 1 March 2015
- Published by Georg Thieme Verlag KG in Journal of Pediatric Neurology
- Vol. 13 (01) , 016-021
Clinical Assessment and Differential Diagnosis of Pediatric Pseudotumor Cerebri Syndrome: Pearls and Pitfalls
Pseudotumor cerebri syndrome (PTCS) is defined by the presence of elevated intracranial pressure in the setting of normal brain parenchyma and normal cytologic and chemical analyses of the cerebrospinal fluid. Pathophysiology of this syndrome remains unclear, while its incidence may be potentially rising in children. The presenting signs and symptoms of PTCS are heterogeneous to usually include headache, papilledema, and visual disturbances (i.e., vision loss or double vision). The clinical features of PTCS in children have changed over the years, making the diagnosis challenging in some cases. Young children may present with atypical symptoms, such as those mimicking a posterior fossa tumor. There are reports of PTCS in children in the absence of headache. Papilledema, considered the acute hallmark of PTCS at onset, can also be absent. It is thus important for pediatricians to recognize atypical presentations especially as previous studies have suggested children presenting with headache in the absence of papilledema or those with papilledema in the absence of any other clinical signs may have increased risk of developing visual constriction deficits and permanent loss of vision, respectively. Moreover, many conditions in the pediatric age group may mimic PTCS, such as migraine and tension headaches. Cerebral venous sinus thrombosis and some neoplastic processes such as gliomatosis cerebri and leptomeningeal spread of hematologic malignancies are known to augment intracranial pressure and have to be carefully excluded. To avoid misdiagnosis and potential long-term sequel, a thorough clinical assessment is crucial to promptly and correctly recognize PTCS.
- 7 October 2014
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 174 (4) , 557-563
Zellweger syndrome and secondary mitochondrial myopathy
Defects in peroxisomes such as those associated with Zellweger syndrome (ZS) can influence diverse intracellular metabolic pathways, including mitochondrial functioning. We report on an 8-month-old female infant and a 6-month-old female infant with typical clinical, radiological and laboratory features of Zellweger syndrome; light microscopic and ultrastructural evidence of mitochondrial pathology in their muscle biopsies; and homozygous pathogenic mutations of the PEX16 gene (c.460 + 5G > A) and the PEX 12 gene (c.888_889 del p.Leu297Thrfs*12), respectively. Additionally, mitochondrial respiratory chain enzymology analysis in the first girl showed a mildly low activity in complexes II–III and IV. We also review five children previously reported in the literature with a presumptive diagnosis of ZS and additional mitochondrial findings in their muscle biopsies. In conclusion, this is the first study of patients with a molecularly confirmed peroxisomal disorder with features of a concomitant mitochondrial myopathy and underscores the role of secondary mitochondrial dysfunction in Zellweger syndrome, potentially contributing to the clinical phenotype.
- 7 October 2014
- Published by Springer Nature in European Journal of Pediatrics
- Vol. 174 (4) , 557-563
Zellweger syndrome and secondary mitochondrial myopathy
Defects in peroxisomes such as those associated with Zellweger syndrome (ZS) can influence diverse intracellular metabolic pathways, including mitochondrial functioning. We report on an 8-month-old female infant and a 6-month-old female infant with typical clinical, radiological and laboratory features of Zellweger syndrome; light microscopic and ultrastructural evidence of mitochondrial pathology in their muscle biopsies; and homozygous pathogenic mutations of the PEX16 gene (c.460 + 5G > A) and the PEX 12 gene (c.888_889 del p.Leu297Thrfs*12), respectively. Additionally, mitochondrial respiratory chain enzymology analysis in the first girl showed a mildly low activity in complexes II–III and IV. We also review five children previously reported in the literature with a presumptive diagnosis of ZS and additional mitochondrial findings in their muscle biopsies. In conclusion, this is the first study of patients with a molecularly confirmed peroxisomal disorder with features of a concomitant mitochondrial myopathy and underscores the role of secondary mitochondrial dysfunction in Zellweger syndrome, potentially contributing to the clinical phenotype.